Full-Time

Group Leader

Drug Product Analytics

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops broad-spectrum bacterial infection vaccines

Biotechnology

Senior, Expert

San Carlos, CA, USA

Required Skills
Data Analysis
Requirements
  • MSc in Pharmaceutics, Chemistry, Biophysics, or Biochemistry preferred
  • 10+ years of industrial experience with MSc or 5+ years of relevant experience with PhD
  • Strong experience in characterization of Biological Drug Products containing proteins, polysaccharides, and/or protein conjugate formulations
  • Experience in testing within GxP environments
  • Experience in method development for HPLC, light scattering analysis, subvisible particle analysis, and visible analysis
  • Experience in authoring analytical technical documents and method transfers
  • Scientific leadership and managerial experience
  • Flexibility, organizational skills, and ability to navigate multiple projects and timelines
  • Strong interpersonal and communication skills
  • Detail-oriented, rigorous, and excellent record-keeping skills
Responsibilities
  • Develop analytical methods and biophysical characterization assays
  • Coordinate routine testing in support of formulation development
  • Manage a team of 3-4 scientists
  • Lead analytical method development and execution for Drug Product characterization
  • Lead a team of scientists to support process development activities
  • Evaluate and develop appropriate biochemical and biophysical characterization tools
  • Apply biophysical characterization techniques to understand antigen/adjuvant interactions
  • Work on multiple projects with fluid prioritization
  • Participate in method transfers to external vendors and internal collaborators
  • Present complex data sets and propose follow-up experiments

Vaxcyte is centered on creating advanced vaccines such as VAX-24, a sophisticated 24-valent pneumococcal conjugate vaccine, by utilizing cutting-edge chemistry and the XpressCF™ cell-free protein synthesis platform. The company prioritizes developing high-fidelity, broad-spectrum vaccines to combat bacterial infections, continuously expanding its product pipeline with innovations like VAX-31 for various bacterial threats.

Company Stage

IPO

Total Funding

$2.3B

Headquarters

San Carlos, California

Founded

2013

Growth & Insights
Headcount

6 month growth

29%

1 year growth

61%

2 year growth

166%